AXOGEN INC

Axogen insider RSU buys reveal board confidence in nerve‑regeneration strategy, suggesting potential upside for investors despite growth‑phase metrics.

Insider buying at Axogen shows board confidence—Levine Alan M. adds 14,150 units at $0, boosting a 336% rally and hinting at future upside.

Axogen insider activity shows routine buy‑sell rebalancing, reflecting Johnson’s strategy of locking gains while keeping long‑term exposure. Investors see confidence in the stock’s value, yet the company’s growth hinges on its nerve‑regeneration pip…

Axogen CFO’s net purchase of 10,796 shares signals confidence amid a volatile market, highlighting potential upside from its nerve‑graft tech pipeline.